Glenmark Specialty and BeiGene sign exclusive deal for marketing cancer drugs Tislelizumab and Zanubrutinib in India.
Glenmark Specialty SA, a unit of Glenmark Pharmaceuticals, has signed an exclusive marketing and distribution deal with global oncology firm BeiGene. The deal includes registering and commercializing cancer drugs Tislelizumab and Zanubrutinib in India. This partnership aims to provide access to innovative oncology treatments across the country, addressing India's rising cancer rates and significant disease burden.
May 21, 2024
5 Articles